Foundation Fighting Blindness

The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just

Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attra

Three biopharmaceutical companies went public in the US on 24 October with different results – Phathom Pharmaceuticals Inc. priced its initial public offering at $19 per share, within a proposed $18

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. ProQR Ge